RLYB (Rallybio Corporation Common Stock) Stock Analysis - AI Report
Rallybio Corporation Common Stock (RLYB) is a publicly traded Healthcare sector company. As of May 21, 2026, RLYB trades at $14.43 with a market cap of $74.70M and a P/E ratio of -5.06. RLYB moved +2.18% today. Year to date, RLYB is +168.41%; over the trailing twelve months it is +427.04%. Its 52-week range spans $1.76 to $15.31. Rallies surfaces RLYB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on RLYB?
Rallies AI research for RLYB combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
ADAR1 Capital Management, LLC bought 10.00K (~$139.82K) on May 19, 2026.
ADAR1 Capital Management, LLC bought 200 (~$2.76K) on May 19, 2026.
ADAR1 Capital Management, LLC bought 6.01K (~$83.98K) on May 18, 2026.
RLYB Analyst Consensus
RLYB analyst coverage data. Average price target: $0.00.
Common questions about RLYB
What is the AI research view on RLYB?
Rallies AI research for RLYB combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for RLYB?
Rallies AI research for RLYB combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is RLYB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RLYB. It does not provide personalized investment advice.